<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625882</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-GCB-401</org_study_id>
    <nct_id>NCT03625882</nct_id>
  </id_info>
  <brief_title>Survey Study for Velaglucerase Alfa (VPRIV) in Japan</brief_title>
  <official_title>VPRIV Drug Use-Result Survey (Japan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-marketing survey study is to collect data to determine the safety
      and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new
      to therapy or have been switched from another therapeutic agent for Gaucher disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2014</start_date>
  <completion_date type="Anticipated">September 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE) Following Initiation of Treatment With Velaglucerase Alfa (VPRIV)</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.An SAE is any event that results in: death; life-threatening; requires inpatient hospitalisation or results in prolongation of existing hospitalisation; persistent or significant disability/incapacity; a congenital anomaly/birth defect or a medically important event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Absence/presence of Anti-velaglucerase Alfa Antibodies</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>Effect of anti-velaglucerase alfa antibodies (including IgGs) will be performed at the physician's discretion per standard clinical practice. Immunoglobulin E (IgE) isotype-specific antibodies will also be measured when clinically indicated (for example, adverse event, serious adverse event or possible of lack of efficacy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Laboratory Assessment</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>Clinically significant changes in laboratory assessments will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypersensitivity Reactions</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>Hypersensitivity reactions are defined as events of drug allergy, angioedema, anaphylactic reaction, anaphylactic shock, anaphylactoid reaction, anaphylaxis prophylaxis, anaphylaxis treatment, drug reaction with eosinophilia and systemic symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrences of Pregnancies/breastfeeding for Women of Child-bearing Potential</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>Pregnancy testing for women of child-bearing potential will be collected throughout the survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin Concentration</measure>
    <time_frame>Baseline, Every 12 weeks up to 8 years</time_frame>
    <description>Hemoglobin concentration will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Platelet Count</measure>
    <time_frame>Baseline, Every 12 weeks up to 8 years</time_frame>
    <description>Platelet count will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Liver Volume</measure>
    <time_frame>Baseline, Every 24 weeks up to 8 years</time_frame>
    <description>Liver volume will be measured at the physician's discretion per standard clinical practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Spleen Volume</measure>
    <time_frame>Baseline, Every 24 weeks up to 8 years</time_frame>
    <description>Spleen volume will be measured at the physician's discretion per standard clinical practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Density</measure>
    <time_frame>Baseline, Every 52 weeks up to 8 years</time_frame>
    <description>Bone density will be assessed at the physician's discretion per standard clinical practice.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Infusion-related Reactions (IRRs)</measure>
    <time_frame>Baseline up to end of the study (8 years)</time_frame>
    <description>Infusion-related reactions are defined as reactions occurring up to 24 hours after the start of the infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with anti-velaglucerase alfa antibodies</measure>
    <time_frame>Baseline up to end of study (8 years)</time_frame>
    <description>Anti-velaglucerase alfa antibodies will be assessed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Gaucher Disease Participants Treated With VPRIV</arm_group_label>
    <description>Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with confirmed Gaucher disease (types 1, 2, or 3) irrespective of any age or
        gender who are either naïve to treatment or participants that have been treated with
        another therapeutic agent for Gaucher disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants with a confirmed diagnosis of Gaucher disease

          -  Participants who are either naïve to treatment or participants that have been treated
             with another therapeutic agent for Gaucher disease

          -  Participants who start VPRIV treatment or transition from VPRIV clinical studies
             during the enrollment period

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konan</name>
      <address>
        <city>Konan</city>
        <state>Aichi</state>
        <zip>483-8704</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>453-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitakyushu</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuyama</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>721-0927</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Higashihiroshima</name>
      <address>
        <city>Higashihiroshima</city>
        <state>Hiroshima</state>
        <zip>739-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obihiro</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <zip>080-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sagamihara</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sendai</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suita</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tondabayashi</name>
      <address>
        <city>Tondabayashi</city>
        <state>Osaka</state>
        <zip>584-0000</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kawagoe</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokorozawa</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moriyama</name>
      <address>
        <city>Moriyama</city>
        <state>Shiga</state>
        <zip>524-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Otsu</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Matsue</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <zip>690-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3125</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>434-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iwata</name>
      <address>
        <city>Iwata</city>
        <state>Shizuoka</state>
        <zip>438-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minato</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sumida-ku</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yonago</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba</name>
      <address>
        <city>Chiba</city>
        <zip>266-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu</name>
      <address>
        <city>Gifu</city>
        <zip>500-8212</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama</name>
      <address>
        <city>Saitama</city>
        <zip>339-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

